LPU
JUNO

Lansdowne Partners (UK)’s Juno Therapeutics, Inc. JUNO Stock Holding History

Lansdowne Partners (UK)’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-20,125
Closed -$379K – 56
2016
Q4 		$379K Hold
20,125
– – ﹤0.01% 44
2016
Q3 		$604K Buy
+20,125
New +$626K 0.01% 39

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Lansdowne Partners (UK)'s JUNO Position: Q1 2017 in Review

Lansdowne Partners (UK) sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2017, closing a stake of 20,125 shares — an estimated $379K sold.

Lansdowne Partners (UK) first reported a position in JUNO in Q3 2016 and held it in 2 quarters. The position peaked at $604K in Q3 2016. 157 funds tracked by Wall St. Rank hold JUNO as of Q1 2017.

  • Lansdowne Partners (UK) reported no remaining Juno Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Lansdowne Partners (UK) sold 20,125 Juno Therapeutics, Inc. shares in Q1 2017, an estimated $379K.
  • Lansdowne Partners (UK) first reported a position in Juno Therapeutics, Inc. in Q3 2016 and held it in 2 quarters.
  • Lansdowne Partners (UK)'s Juno Therapeutics, Inc. position peaked at $604K in Q3 2016.
  • 157 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2017.

Based on Lansdowne Partners (UK)'s 13F filing for Q1 2017, filed 12 May 2017.